Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

Inclusion Criteria

• •1. Written Informed Consent Form signed voluntarily before the first study-related activity.
• •2. Aged between 18 and 70 years, inclusive.
• •3. Subjects with a history of the cardinal symptoms of GERD (both heartburn and regurgitation) prior to PPI therapy.
• •4. Subjects with symptoms of GERD for at least 6 months prior to the Screening Visit.
• •5. Subjects who have persistent symptoms of regurgitation for 3 or more days over the past week with or without heartburn while on PPI.
• •6. Subjects have at least some improvement to the symptom of heartburn while on PPI therapy.
• •7. Subjects on PPI therapy for at least 8 weeks prior to the Screening Visit of which the last 4 weeks are on a stable labeled dose for any GERD indication according to the country label, where a change of PPI therapy would not impact the symptoms (twice-daily dosing of PPI is not allowed in the last 4 weeks)